TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35854296

Group type: EXPERIMENTAL
Intervention: Carer Matters programme (including needs assessment, educational resources, tele-support, and training courses)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tele-support provided to caregivers reporting high burden (69 caregivers)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Caregiver training courses attended by 252 caregivers
Number of subjects: 550
Study: 35854318

Group type: EXPERIMENTAL
Intervention: Exposure to moral distress during the COVID-19 pandemic
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Perception of inappropriate care
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Patients dying with dignity
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Palliative care practice changes during the pandemic
Number of subjects: 313
Study: 35854321

Group type: EXPERIMENTAL
Intervention: ATLAS 2030 gait exoskeleton, used for nine sessions bi-weekly of 60 min each.
Number of subjects: 3
Study: 35854324

Group type: EXPERIMENTAL
Intervention: Mental distress during TB investigation and treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mental distress symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Individual level drivers of mental distress
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social, economic and health system level drivers of mental distress
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Economic stress of poverty
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Measures to support TB patients
Number of subjects: 80
Study: 35854330

Group type: EXPERIMENTAL
Intervention: QoL-HHT questionnaire (24 items measuring 6 domains of QOL)
Number of subjects: 643
Study: 35854375

Group type: EXPERIMENTAL
Intervention: Educational intervention within the KUPA project
Number of subjects: 39
Study: 35854388

Group type: EXPERIMENTAL
Intervention: Pro-DLB group (148 patients)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Pro-DLB group
Number of subjects: 892

Group type: COMPARATOR
Intervention: NS group (control)
Number of subjects: 892

Group type: COMPARATOR
Intervention: 1S group (control)
Number of subjects: 892
Study: 35854392

Group type: EXPERIMENTAL
Intervention: Unified Internet-delivered exposure treatment
Number of subjects: 33
Study: 35854467

Group type: EXPERIMENTAL
Intervention: MRI/MRCP screening
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 75
Study: 35854937

Group type: EXPERIMENTAL
Intervention: DHA status (measured by RBC DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA intake (dietary)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA intake
Number of subjects: 0
Study: 35854939

Group type: EXPERIMENTAL
Intervention: Fathers' complementary feeding support (≥2 actions)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Parents' perspectives of mothers' autonomy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Parents' perspectives of fathers' complementary feeding support
Number of subjects: 495
Study: 35855534

Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients with mild OSA (AHI ≥ 5 events/h)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Matched controls with mild OSA (AHI ≥ 5 events/h)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Risk of mild OSA in sarcoidosis patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Impact of OSA on sleepiness and fatigue in sarcoidosis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Risk factors for OSA in sarcoidosis patients
Number of subjects: 71
Study: 35855645

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 409
Study: 35856081

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Isatuximab (experimental arm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regorafenib (control arm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hybrid-control design (integrating historical trial data)
Number of subjects: 30
Study: 35856671

Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept uptake in PWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Noncalcified aortic plaque volume in PWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Systemic levels of caspase-1 in PWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD14-CD16+ monocytes in PWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD8+ T cells in PWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD4+/CD8+ T-cell ratio in PWH
Number of subjects: 30
Study: 35856836

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35856908

Group type: EXPERIMENTAL
Intervention: Greater morning actigraphic physical activity from 9:00 to 12:00
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Greater afternoon activity from 12:00 to 15:00
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Afternoon physical activity from 12:00 to 15:00
Number of subjects: 134
Study: 35857060

Group type: EXPERIMENTAL
Intervention: Second-line treatment for T2DM
Number of subjects: 1798
Study: 35857365

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 982
Study: 35857405

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day, orally, 2 weeks on and 1 week off, every 3 weeks) plus Toripalimab (240 mg, intravenously over 60 minutes, once every 2 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anlotinib plus Toripalimab
Number of subjects: 29
Study: 35857579

Group type: EXPERIMENTAL
Intervention: Intradermal delivery of tremelimumab (2 to 20 mg)
Number of subjects: 13
Study: 35857660

Group type: EXPERIMENTAL
Intervention: FLT180a (verbrinacogene setparvovec) gene therapy at varying doses (3.84×10^11 vg/kg) with glucocorticoids and/or tacrolimus for immunosuppression
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FLT180a (verbrinacogene setparvovec) gene therapy
Number of subjects: 10
Study: 35858168

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35858254

Group type: EXPERIMENTAL
Intervention: VR physical exercises at home for 6 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VR mental exercises through applications
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VR exercises (physical, relaxing, and cognitive)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VR exercises
Number of subjects: 48
Study: 35858373

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N8-GP
Number of subjects: 80
Study: 35858479

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention (CP)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (no CP intervention)
Number of subjects: 284
Study: 35858538

Group type: EXPERIMENTAL
Intervention: Maternal age 16-24 years
Number of subjects: 16518

Group type: EXPERIMENTAL
Intervention: Maternal age 25-34 years
Number of subjects: 16518

Group type: EXPERIMENTAL
Intervention: Maternal age 35-44 years
Number of subjects: 16518

Group type: EXPERIMENTAL
Intervention: Maternal age 45-54 years
Number of subjects: 16518
Study: 35858586

Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine (modified vaccinia virus Ankara-based vaccine) administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months.
Number of subjects: 0
Study: 35858774

Group type: EXPERIMENTAL
Intervention: Paroxysmal atrial fibrillation (PAF)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Blood biomarkers
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 417
Study: 35858775

Group type: EXPERIMENTAL
Intervention: Post-first wave (June-August 2020)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: April-June 2021
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Minority ethnic groups
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Children <10 years
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Overall seropositive participants
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Participants aged 15-18 years
Number of subjects: 1000
Study: 35858849

Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT) using TheraSpheres
Number of subjects: 24
Study: 35858863

Group type: EXPERIMENTAL
Intervention: Upper limb functional index-Urdu (ULFI-U)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Numeric pain rating scale (NPRS)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Quick Disability of arm, shoulder, and hand (QuickDash)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Health survey (SF-12)
Number of subjects: 250
Study: 35858894

Group type: EXPERIMENTAL
Intervention: LIQOSEAL
Number of subjects: 228

Group type: COMPARATOR
Intervention: FDA-approved PEG sealant
Number of subjects: 228
Study: 35858899

Group type: EXPERIMENTAL
Intervention: ICU-treated COVID-19 patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: ICU-treated COVID-19 patients with more than 12 years of education
Number of subjects: 213
Study: 35858989

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens (NAc)
Number of subjects: 6
Study: 35859001

Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at 15 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at one month
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at three months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Factors associated with PTSD symptoms
Number of subjects: 100
Study: 35859065

Group type: EXPERIMENTAL
Intervention: Web-based exercise program delivered by a patient organisation
Number of subjects: 35
Study: 35860245

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (BM-MSCs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (standard therapy with dexamethasone)
Number of subjects: 32
Study: 35860581

Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiation therapy (3D-CRT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no arrhythmia)
Number of subjects: 116
Study: 35860587

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 551

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 551
Study: 35860743

Group type: EXPERIMENTAL
Intervention: 1273-mRNA
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: BNT162b2-mRNA
Number of subjects: 193

Group type: COMPARATOR
Intervention: No booster vaccination
Number of subjects: 193
Study: 35860752

Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Moderate circulatory failure
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Severe circulatory failure
Number of subjects: 584
Study: 35860926

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 0
Study: 35861072

Group type: EXPERIMENTAL
Intervention: Prehospital administration of thawed plasma (TP)
Number of subjects: 149
Study: 35861129

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35861296

Group type: EXPERIMENTAL
Intervention: Higher-dose rifampicin (35 mg/kg)
Number of subjects: 128
Study: 35861370

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity
Number of subjects: 43
Study: 35861464

Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in asthma patients
Number of subjects: 11226

Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in COPD patients
Number of subjects: 11226

Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in asthma + COPD patients
Number of subjects: 11226

Group type: COMPARATOR
Intervention: Comparison of TTs prevalence in primary vs specialized clinics
Number of subjects: 11226

Group type: EXPERIMENTAL
Intervention: Relationship of TTs to diagnosis and severity of disease
Number of subjects: 11226

Group type: EXPERIMENTAL
Intervention: Patterns of TTs presence and absence
Number of subjects: 11226
Study: 35861632

Group type: EXPERIMENTAL
Intervention: Tafasitamab and lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic control groups
Number of subjects: 0
Study: 35861706

Group type: EXPERIMENTAL
Intervention: Online support group participation (3 times weekly for 6 weeks)
Number of subjects: 20
Study: 35861778

Group type: EXPERIMENTAL
Intervention: Posaconazole (PCZ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10
Study: 35861811

Group type: EXPERIMENTAL
Intervention: Patients in the convalescent group (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients in the recovered group (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients in the acute group (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 90
Study: 35861814

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) ECG+ (n=74)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) ECG- (n=206)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (without AF)
Number of subjects: 280
Study: 35861828

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance for PCI
Number of subjects: 2848
Study: 35861979

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: High RC/low LDL-C group
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: RC quartiles
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 6544
Study: 35862024

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 1621
Study: 35862034

Group type: EXPERIMENTAL
Intervention: Elo-KRd (elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone)
Number of subjects: 46
Study: 35862035

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg 3 times daily) until disease progression, death, or treatment discontinuation.
Number of subjects: 116
Study: 35862126

Group type: EXPERIMENTAL
Intervention: Psychological variables (depressive symptoms, well-being, quality of life)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Psychological variables (well-being, mental health components of quality of life)
Number of subjects: 185
Study: 35862141

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Coronary angiography and hsTnT and hsTnI concentrations
Number of subjects: 1829
Study: 35862184

Group type: EXPERIMENTAL
Intervention: mHealth app (BMT4me) designed to promote adherence to immunosuppressant medication and track symptoms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: mHealth app (BMT4me)
Number of subjects: 15
Study: 35862185

Group type: EXPERIMENTAL
Intervention: Remote monitoring solutions implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technology Acceptance Model questionnaire
Number of subjects: 0
Study: 35862692

Group type: EXPERIMENTAL
Intervention: REsOluTioN online resilience training program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 100
Study: 35862743

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP) 2.1/17.1 mg/kg, administered monthly for 3 consecutive months.
Number of subjects: 82
Study: 35863354

Group type: EXPERIMENTAL
Intervention: Noncurative ESD for CRC lesions
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Surgery after noncurative ESD
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Noncurative ESD for sm1 cancers
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Noncurative ESD for >sm1 cancers without risk factors
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NC-Lymph score (risk factors for lymph node metastasis)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NC-Wall score (risk factors for residual lesions in the wall)
Number of subjects: 135
Study: 35863672

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (level 2 dose at 75 mg/m²), capecitabine, and radiation therapy after induction chemotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Type I IR
Number of subjects: 23
Study: 35863747

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) lowering
Number of subjects: 26
Study: 35863789

Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 10480
Study: 35863844

Group type: EXPERIMENTAL
Intervention: Early rhythm control (ERC)
Number of subjects: 2785
Study: 35864209

Group type: EXPERIMENTAL
Intervention: 150 mm Drug-Coated Balloon (DCB)
Number of subjects: 107
Study: 35865219

Group type: EXPERIMENTAL
Intervention: Chicken liver and eggshell crackers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35865463

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx) testing prior to chemotherapy initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx) testing
Number of subjects: 0
Study: 35865476

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (250 ml/12 h, increased daily to 1000 ml/12 h if tolerated)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Oral nutrition
Number of subjects: 128
Study: 35866376

Group type: EXPERIMENTAL
Intervention: Standard care with regular dental examinations at three-month intervals and preventive treatments (including antibiotics before dental extractions and techniques for wound closure)
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors inserted into the postextraction alveolus plus standardised medical and surgical care
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Delicate surgery and closure by primary intention
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Primary closure of the extraction socket with a mucoperiosteal flap
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Subperiosteal wound closure
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment in addition to standard care
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Autofluorescence-guided bone surgery
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Autofluorescence-guided sequestrectomy
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin after bone surgery
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein-2 with platelet-rich fibrin
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Concentrated growth factor and primary wound closure
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Teriparatide 20 μg daily
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Teriparatide 56.5 μg weekly
Number of subjects: 1668
Study: 35866563

Group type: EXPERIMENTAL
Intervention: ACTIVLIM-CP questionnaire
Number of subjects: 89
Study: 35866657

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 388

Group type: COMPARATOR
Intervention: No Rocuronium
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: AWP presence
Number of subjects: 388
Study: 35866984

Group type: EXPERIMENTAL
Intervention: Cranial PET/CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracranial PET/CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined cranial and extracranial PET/CT
Number of subjects: 0
Study: 35867023

Group type: EXPERIMENTAL
Intervention: Functional 3D Laparoscopes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35867076

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35867239

Group type: EXPERIMENTAL
Intervention: Transcrestal sinus floor elevation with injectable xenograft in gel form
Number of subjects: 71
Study: 35867382

Group type: EXPERIMENTAL
Intervention: AR group
Number of subjects: 30
Study: 35867385

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (1.1 GBq and 3.7 GBq groups)
Number of subjects: 139
Study: 35867393

Group type: EXPERIMENTAL
Intervention: +Change
Number of subjects: 24
Study: 35867399

Group type: EXPERIMENTAL
Intervention: SADL-eM (Spinal Cord Injury Activities of Daily Living Education Manual)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SADL-eM
Number of subjects: 90
Study: 35867403

Group type: EXPERIMENTAL
Intervention: SOLUS-D with guidance
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: SOLUS-D without guidance
Number of subjects: 250

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 250
Study: 35867411

Group type: EXPERIMENTAL
Intervention: Vaccinated health care workers
Number of subjects: 425

Group type: COMPARATOR
Intervention: Unvaccinated health care workers
Number of subjects: 425
Study: 35867672

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) monitoring using Cepheid Xpert
Number of subjects: 541

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) monitoring using Roche COBAS (v2.0)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) monitoring
Number of subjects: 541

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) monitoring
Number of subjects: 541
Study: 35867947

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg orally once daily)
Number of subjects: 46
Study: 35867951

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks
Number of subjects: 103
Study: 35867966

Group type: EXPERIMENTAL
Intervention: Baseline neuropsychological indicators (age, memory, speed scores)
Number of subjects: 80
Study: 35868533

Group type: EXPERIMENTAL
Intervention: 250 ppm inhaled carbon monoxide (CO)
Number of subjects: 0
Study: 35868830

Group type: EXPERIMENTAL
Intervention: Admissions to forensic settings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline measures of symptomatology of schizophrenia and violence risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient related measures
Number of subjects: 0